SEARCH

SEARCH BY CITATION

References

  • 1
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989; 298: 8286.
  • 2
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955; 4947: 10411048.
  • 3
    Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978; 13: 833837.
  • 4
    Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987; 92: 18941898.
  • 5
    Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut. 1989; 30: 12361240.
  • 6
    Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995; 80: 252267.
  • 7
    Baveye S, Elass E, Mazurier J, et al. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med. 1999; 37: 281286.
  • 8
    Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol. 1992; 30: 12381242.
  • 9
    Kayazawa M, Saitoh O, Kojima K, et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 2002; 97: 360369.
    Direct Link:
  • 10
    Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003; 98: 13091314.
    Direct Link:
  • 11
    Parsi MA, Shen B, Achkar JP, et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology. 2004; 126: 12801286.
  • 12
    Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol. 2001; 7: 460465.
  • 13
    Fine KD, Ogunji F, George J, et al. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol. 1998; 93: 13001305.
    Direct Link:
  • 14
    Poullis A, Foster R, Northfield TC, et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16: 675681.
  • 15
    Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002; 123: 450460.
  • 16
    Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000; 47: 506513.
  • 17
    Kristinsson J, Armbruster CH, Ugstad M, et al. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol. 2001; 36: 202207.
  • 18
    Kronborg O, Ugstad M, Fuglerud P, et al. Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut. 2000; 46: 795800.
  • 19
    Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000; 95: 28312837.
    Direct Link:
  • 20
    Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004; 39: 10171020.
  • 21
    Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119: 1522.
  • 22
    Saitoh O, Kojima K, Kayazawa M, et al. Comparison of tests for fecal lactoferrin and fecal occult blood for colorectal diseases: a prospective pilot study. Intern Med. 2000; 39: 778782.
  • 23
    Saitoh O, Sugi K, Matsuse R, et al. The forms and the levels of fecal PMN-elastase in patients with colorectal diseases. Am J Gastroenterol. 1995; 90: 388393.
  • 24
    Andus T, Gross V, Caesar I, et al. PMN-elastase in assessment of patients with inflammatory bowel disease. Dig Dis Sci. 1993; 38: 16381644.
  • 25
    Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol. 1992; 27: 139142.
  • 26
    Stamp GW, Poulsom R, Chung LP, et al. Lysozyme gene expression in inflammatory bowel disease. Gastroenterology. 1992; 103: 532538.
  • 27
    van der Sluys Veer A, Brouwer J, Biemond I, et al. Fecal lysozyme in assessment of disease activity in inflammatory bowel disease. Dig Dis Sci. 1998; 43: 590595.
  • 28
    Costongs GM, Hemrika MH, Engels LG, et al. Faecal lysozyme: determination, reference intervals and some data in gastro-intestinal disease. Clin Chim Acta. 1987; 167: 125134.
  • 29
    Sugi K, Saitoh O, Hirata I, et al. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 1996; 91: 927934.
  • 30
    Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005; 54: 364368.
  • 31
    Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001; 96: 26832687.
  • 32
    Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004; 13: 279284.
  • 33
    Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992; 27: 793798.